Journal Club: Gene-Agnostic Gene Therapy to Preserve Vision
Striatech is pleased to announce its next Journal Club: Gene-Agnostic Gene Therapy to Preserve Vision, which will be held on
Read more
DISEASES
Enhancing RPE Metabolism to Protect Cone Vision in Retinitis Pigmentosa
Boosting RPE Metabolic Support Offers a Promising Gene-Independent Strategy for RP Treatment A Striatech .pdf Case Study Retinitis Pigmentosa (RP)
Read more
Boosting Retinal Metabolism to Preserve Cone Function
A recent study from Constance Cepko’s group at Harvard Medical School offers an encouraging advance toward therapeutic strategies for Retinitis
Read more
Time-Kill Assay Services for Antimicrobial Development
Antiinfectives Intelligence (Aii) offers state-of-the-art Time-Kill Assay services to evaluate the dynamic killing effects of antimicrobial agents. This advanced method
Read more
Irish Biotech Startup Aerska Secures $21M to Push Boundaries of Brain RNAi Therapies
Aerska, a newly formed biotechnology company focused on transforming the treatment of neurological diseases, has officially launched with $21 million
Read more
The Role of Microglia and T Cells in Age-Associated Decline
A recent study by Janos Groh and colleagues in Mikael Simons’ group at the Institute of Neuronal Cell Biology, Technical
Read more
Roche to Acquire 89bio in $3.5 Billion Deal Bolstering its MASH Pipeline
The definitive merger agreement, valued at up to $3.5 billion, grants Roche control of the late-stage FGF21 analog, pegozafermin, for
Read more
Merck’s KEYTRUDA QLEX™ Secures FDA Approval as First Subcutaneous Pembrolizumab Injection
Merck & Co., known as MSD outside of the United States and Canada, announced on Saturday that the U.S. Food
Read more
FDA Approves J&J’s Inlexzo™ Breakthrough Bladder Cancer Therapy
Johnson & Johnson has announced that the U.S. Food and Drug Administration (FDA) has approved INLEXZO™ (gemcitabine intravesical system), a
Read more
Boehringer’s HERNEXEOS® Wins Accelerated FDA Nod in Lung Cancer
In a landmark decision for HER2-mutant lung cancer, the US FDA has granted accelerated approval to Boehringer Ingelheim’s HERNEXEOS® (zongertinib),
Read more